Linking signaling pathways to transcriptional programs in breast cancer

Genome Research

Volumn 24, Issue 11, 2014, Pages 1869-1880

  Osmanbeyoglu, Hatice U ^a   Pelossof, Raphael ^a   Bromberg, Jacqueline F ^b   Leslie, Christina S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HIGH MOBILITY GROUP PROTEIN; INTERFERON REGULATORY FACTOR 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 14; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN BCL 2; PROTEIN MSH6; SMAD4 PROTEIN; STAT5A PROTEIN; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR NKX2.2; TRANSCRIPTION FACTOR SOX9; ANTINEOPLASTIC AGENT; TRANSCRIPTION FACTOR;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GENETICS; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LOW RISK PATIENT; LUMINAL A BREAST CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; REVERSE PHASE PROTEIN ARRAY; STATISTICAL ANALYSIS; ALGORITHM; BIOLOGICAL MODEL; BREAST NEOPLASMS; CLUSTER ANALYSIS; DNA MICROARRAY; DRUG EFFECTS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MULTIVARIATE ANALYSIS; PROCEDURES; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MODELS, GENETIC; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ARRAY ANALYSIS; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84929456295     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.173039.114     Document Type: Article

References (75)

1. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, Causton HC, Pochanard P, Mozes E, Garraway LA, Pe'er D. 2010. An integrated approach to uncover drivers of cancer. Cell 143: 1005-1017.
2. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H. 2007. FOXA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res 13: 4415-4421.
3. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
4. Bartholomeusz C, Itamochi H, Nitta M, Saya H, Ginsberg MH, Ueno NT. 2006. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene 25: 79-90.
5. Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, et al. 2010. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin Cancer Res 16: 1802-1811.
6. Baselga J. 2011. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 16 (Suppl 1): 12-19.
7. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al. 2012. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366: 109-119.
8. Boutsikou E, Kontakiotis T, Zarogoulidis P, Darwiche K, Eleptheriadou E, Porpodis K, Galaktidou G, Sakkas L, Hohenforst-Schmidt W, Tsakiridis K, et al. 2013. Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. Onco Targets Ther 6: 125-134.
9. Bustin M, Reeves R. 1996. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 54: 35-100.
10. Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Iorfida M, Mazza M, Balduzzi A, et al. 2013. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol 24: 661-668.
11. The Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
12. Chakravarty G, Moroz K, Makridakis NM, Lloyd SA, Galvez SE, Canavello PR, Lacey MR, Agrawal K, Mondal D. 2011a. Prognostic significance of cytoplasmic SOX9 in invasive ductal carcinoma and metastatic breast cancer. Exp Biol Med (Maywood) 236: 145-155.
13. Chakravarty G, Rider B, Mondal D. 2011b. Cytoplasmic compartmentalization of SOX9 abrogates the growth arrest response of breast cancer cells that can be rescued by trichostatin A treatment. Cancer Biol Ther 11: 71-83.
14. Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J. 2010. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 116: 4227-4237.
15. Churchill ME, Changela A, Dow LK, Krieg AJ. 1999. Interactions of high mobility group box proteins with DNA and chromatin. Methods Enzymol 304: 99-133.
16. Ciriello G, Sinha R, Hoadley KA, Jacobsen AS, Reva B, Perou CM, Sander C, Schultz N. 2013. The molecular diversity of Luminal A breast tumors. Breast Cancer Res Treat 141: 409-420.
17. Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK. 2012. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res 14: R108.
18. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. 2012. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486: 346-352.
19. Derry JM, Mangravite LM, Suver C, Furia MD, Henderson D, Schildwachter X, Bot B, Izant J, Sieberts SK, Kellen MR, et al. 2012. Developing predictive molecular maps of human disease through community-based modeling. Nat Genet 44: 127-130.
20. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, et al. 2007. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13: 3207-3214.
21. Doss S, Garrett Z, Sutcliffe F, Stevens A. 2012. NICE guidance on rituximab for first-line treatment of symptomatic stage III-IV follicular lymphoma in previously untreated patients. Lancet Oncol 13: 128-130.
22. Dydensborg AB, Rose AA, Wilson BJ, Grote D, Paquet M, Giguere V, Siegel PM, Bouchard M. 2009. GATA3 inhibits breast cancer growth and pulmonary breast cancer metastasis. Oncogene 28: 2634-2642.
23. Fedele CG, Ooms LM, Ho M, Vieusseux J, O'Toole SA, Millar EK, Lopez-Knowles E, Sriratana A, Gurung R, Baglietto L, et al. 2010. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci 107: 22231-22236.
24. Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, et al. 2006. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res 12: 6826-6835.
25. Friedman J, Hastie T, Tibshirani R. 2010. Regularization paths for generalized linear models via coordinate descent. J Stat Softw 33: 1-22.
26. Gagliardi PA, di Blasio L, Orso F, Seano G, Sessa R, Taverna D, Bussolino F, Primo L. 2012. 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner. Neoplasia 14: 719-731.
27. Gayle SS, Arnold SL, O'Regan RM, Nahta R. 2012. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance. Anticancer Agents Med Chem 12: 151-162.
28. Giordano C, Vizza D, Panza S, Barone I, Bonofiglio D, Lanzino M, Sisci D, De Amicis F, Fuqua SA, Catalano S, et al. 2013. Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells. Mol Oncol 7: 379-391.
29. Haibe-Kains B, El-Hachem N, Birkbak NJ, Jin AC, Beck AH, Aerts HJ, Quackenbush J. 2013. Inconsistency in large pharmacogenomic studies. Nature 504: 389-393.
30. Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, Press MF. 2012. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev 21: 1848-1855.
31. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, et al. 2012. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci 109: 2724-2729.
32. Huang SS, Clarke DC, Gosline SJ, Labadorf A, Chouinard CR, Gordon W, Lauffenburger DA, Fraenkel E. 2013. Linking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling. PLoS Comput Biol 9: e1002887.
33. The International Cancer Genome Consortium. 2010. International network of cancer genome projects. Nature 464: 993-998.
34. Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, Quraishi AA, Ignatoski KW, Daignault S, Davis A, et al. 2013. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 73: 1635-1646.
35. Kashiwagi S, Yashiro M, Takashima T, Aomatsu N, Kawajiri H, Ogawa Y, Onoda N, Ishikawa T, Wakasa K, Hirakawa K. 2013. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer. Br J Surg 100: 490-496.
36. Khatri P, Sirota M, Butte AJ. 2012. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput Biol 8: e1002375.
37. Kim HS, Park I, Cho HJ, Gwak G, Yang K, Bae BN, Kim KW, Han S, Kim HJ, Kim YD. 2012. Analysis of the potent prognostic factors in luminal-type breast cancer. J Breast Cancer 15: 401-406.
38. Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S, Quraishi AA, Tawakkol N, D'Angelo R, Paulson AK, et al. 2012. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 47: 570-584.
39. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z. 2008. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13: 141-152.
40. Lan A, Smoly IY, Rapaport G, Lindquist S, Fraenkel E, Yeger-Lotem E. 2011. ResponseNet: revealing signaling and regulatory networks linking genetic and transcriptomic screening data. Nucleic Acids Res 39: W424-429.
41. Li Q, Wu L, Oelschlager DK, Wan M, Stockard CR, Grizzle WE, Wang N, Chen H, Sun Y, Cao X. 2005. Smad4 inhibits tumor growth by inducing apoptosis in estrogen receptor-a-positive breast cancer cells. J Biol Chem 280: 27022-27028.
42. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, Yang JY, Broom BM, Verhaak RG, Kane DW, et al. 2013. TCPA: a resource for cancer functional proteomics data. Nat Methods 10: 1046-1047.
43. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. 2011. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27: 1739-1740.
44. Lincoln DW 2nd, Bove K. 2005. The transcription factor Ets-1 in breast cancer. Front Biosci 10: 506-511.
45. Mancini M, Toker A. 2009. NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 9: 810-820.
46. Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R, Califano A. 2006. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 7 (Suppl 1): S7.
47. Matheu A, Collado M, Wise C, Manterola L, Cekaite L, Tye AJ, Canamero M, Bujanda L, Schedl A, Cheah KS, et al. 2012. Oncogenicity of the developmental transcription factor Sox9. Cancer Res 72: 1301-1315.
48. Milde-Langosch K, Loning T, Bamberger AM. 2003. Expression of the CCAAT/enhancer-binding proteins C/EBPa, C/EBPb and C/EBPd in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins. Breast Cancer Res Treat 79: 175-185.
49. Mylona EE, Alexandrou PT, Giannopoulou IA, Rafailidis PI, Markaki S, Keramopoulos A, Nakopoulou LL. 2006. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype. Cancer Detect Prev 30: 111-117.
50. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al. 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
51. Okui T, Shimo T, Fukazawa T, Mohammad Monsur Hassan N, Honami T, Ibaragi S, Takaoka M, Naomoto Y, Sasaki A. 2013. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma. Curr Cancer Drug Targets 13: 289-299.
52. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al. 2009. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
53. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin IE, Liotta LA. 2001. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20: 1981-1989.
54. Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E, Freydin B, Yang N, Ertel A, Tran TH, et al. 2012. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res 14: R130.
55. Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y, Rosato A, Sgarra R, Del Sal G, Manfioletti G. 2013. HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget 4: 1293-1308.
56. Peluso S, Chiappetta G. 2010. High-mobility group A (HMGA) proteins and breast cancer. Breast Care (Basel) 5: 81-85.
57. Prat A, Cheang MC, Martin M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, et al. 2013. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31: 203-209.
58. Robens J, Goldstein L, Gown AM, Schnitt SJ. 2010. Thyroid transcription factor-1 expression in breast carcinomas. Am J Surg Pathol 34: 1881-1885.
59. Segal E, Friedman N, Koller D, Regev A. 2004. A module map showing conditional activity of expression modules in cancer. Nat Genet 36: 1090-1098.
60. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. 2003. Cytoscape: a software environment for integrated modelsof biomolecular interaction networks. Genome Res 13: 2498-2504.
61. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci 100: 8418-8423.
62. Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV, Sweep CG. 2002. Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival inbreast cancer. Oncogene 21: 8506-8509.
63. Switzer CH, Cheng RY, Ridnour LA, Glynn SA, Ambs S, Wink DA. 2012. Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer. Breast Cancer Res 14: R125.
64. Therneau TM. 1997. A package for survival analysis in S. Mayo Clinic Foundation, Rochester, MN.
65. Tuncbag N, Braunstein A, Pagnani A, Huang SS, Chayes J, Borgs C, Zecchina R, Fraenkel E. 2013. Simultaneous reconstruction of multiple signaling pathways via the prize-collecting Steiner forest problem. J Comput Biol 20: 124-136.
66. Ueno NT, Zhang D. 2011. Targeting EGFR in triple negative breast cancer. J Cancer 2: 324-328.
67. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
68. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM. 2010. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26: i237-i245.
69. von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. 2003. STRING: a database ofpredicted functional associations between proteins. Nucleic Acids Res 31: 258-261.
70. Wang K, Saito M, Bisikirska BC, Alvarez MJ, Lim WK, Rajbhandari P, Shen Q, Nemenman I, Basso K, Margolin AA, et al. 2009. Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol 27: 829-839.
71. Wilson BJ, Giguere V. 2008. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor a pathway. Mol Cancer 7: 49.
72. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et al. 2013. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 41: D955-D961.
73. Yiu GK, Toker A. 2006. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J Biol Chem 281: 12210-12217.
74. Yosef N, Ungar L, Zalckvar E, Kimchi A, Kupiec M, Ruppin E, Sharan R. 2009. Toward accurate reconstruction of functional protein networks. Mol Syst Biol 5: 248.
75. Zahnow CA. 2009. CCAAT/enhancer-binding protein b: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med 11: e12.